Sonrotoclax and dexamethasone with or without daratumumab for AL amyloidosis with t(11;14)
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary AL amyloidosis (a protein disorder).
- You are 18 years or older.
- A genetic test (FISH) shows you have the t(11;14) change in your cells.
- You are able to do daily activities without major limitations (ECOG score 0-2).
- Your disease can be measured through blood tests showing abnormal protein levels.
- Your heart, liver, kidneys, and blood counts are working well enough (specific lab values needed).
- You have not taken a BCL-2 inhibitor before (like venetoclax).
- You do not have active multiple myeloma or other advanced cancers.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs, sonrotoclax and a BCMA bispecific antibody, for people newly diagnosed with AL amyloidosis. The treatment aims to target and destroy the abnormal cells that cause the disease, potentially improving outcomes.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Hear when a new AL Amyloidosis (AL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.